MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Home・Aandelen Lijst・Cogent Biosciences Inc

Cogent Biosciences Inc

Open

4.39 -2.01

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.29

Max

4.51

Belangrijke statistieken
By Trading Economics
Inkomsten	2.7M -68M
EPS	-0.09
Werknemers	205
EBITDA	1.7M -73M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+269.62% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-327M 498M
Vorige openingsprijs	6.4
Vorige sluitingsprijs	4.39

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

4.26 / 4.64 Steun & Weerstand

Cogent Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 apr 2025, 23:54 UTC

Populaire aandelen

Stocks to Watch: Alphabet, Intel, AppFolio

24 apr 2025, 23:51 UTC

Marktinformatie

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 apr 2025, 23:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

24 apr 2025, 23:46 UTC

Marktinformatie

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 apr 2025, 23:37 UTC

Top Nieuws

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 apr 2025, 23:36 UTC

Top Nieuws

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 apr 2025, 23:13 UTC

Top Nieuws

Winsten

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 apr 2025, 23:09 UTC

Top Nieuws

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 apr 2025, 23:02 UTC

Acquisities, Fusies, Overnames

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 apr 2025, 23:02 UTC

Acquisities, Fusies, Overnames

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 apr 2025, 22:51 UTC

Top Nieuws

Acquisities, Fusies, Overnames

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 apr 2025, 22:48 UTC

Top Nieuws

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 apr 2025, 22:47 UTC

Marktinformatie

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 apr 2025, 22:38 UTC

Marktinformatie

Winsten

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 apr 2025, 22:24 UTC

Winsten

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 apr 2025, 22:24 UTC

Winsten

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 apr 2025, 22:24 UTC

Marktinformatie

Winsten

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 apr 2025, 22:23 UTC

Winsten

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 apr 2025, 22:11 UTC

Marktinformatie

Winsten

Global Equities Roundup: Market Talk

24 apr 2025, 22:11 UTC

Marktinformatie

Winsten

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 apr 2025, 22:09 UTC

Top Nieuws

Winsten

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 apr 2025, 22:00 UTC

Marktinformatie

Winsten

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 apr 2025, 21:39 UTC

Top Nieuws

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 apr 2025, 21:24 UTC

Top Nieuws

Winsten

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 apr 2025, 21:24 UTC

Top Nieuws

Winsten

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 apr 2025, 21:23 UTC

Top Nieuws

Winsten

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 apr 2025, 21:04 UTC

Winsten

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 apr 2025, 21:03 UTC

Winsten

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 apr 2025, 21:03 UTC

Winsten

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 apr 2025, 21:02 UTC

Winsten

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Peer Vergelijking

Prijswijziging

Cogent Biosciences Inc Prognose

Koersdoel

By TipRanks

269.62% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 16.67 USD 269.62%

Hoogste 24 USD

Laagste 8 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cogent Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Cogent Biosciences Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

4.26 / 4.64Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.